U. Galili, U. Galili, and J. Avila, Evolution of a 1,3Galactosyltransferase and of the a- Gal epitope In a-Gal and Anti-Gal: a-1,3-galactosyltransferase, a- Gal epitopes, and the natural anti-Gal antibody Edited by, pp.1-18

U. Galili, S. Shohet, E. Kobrin, C. Stults, and B. Macher, Man, apes, and Old World monkeys differ from other mammals in the expression of alpha-galactosyl epitopes on nucleated cells, J Biol Chem, vol.263, pp.17755-17762, 1988.

M. Lanteri, V. Giordanengo, N. Hiraoka, J. Fuzibet, P. Auberger et al., Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death, Glycobiology, vol.13, issue.12, pp.909-918, 2003.
DOI : 10.1093/glycob/cwg110

U. Galili and J. Avila, Anti-Gal: a-1,3-galactosyltransferase, a-Gal epitopes, and the natural anti-Gal antibody, 1999.

G. Hortobagyi, M. Hung, and G. Lopez-berestein, or Epithelial Ovarian Cancer. M.D. Anderson Cancer Center, Houston, Texas, Human Gene Therapy, vol.9, issue.12, pp.1775-1798, 1998.
DOI : 10.1089/hum.1998.9.12-1775

L. Buhler, T. Friedman, J. Iacomini, and D. Cooper, Xenotransplantation - state of the art - Update 1999, Frontiers in Bioscience, vol.4, issue.1-3, pp.416-432, 1999.
DOI : 10.2741/Buhler

U. Jager, Y. Takeuchi, and C. Porter, Sensitization of Human Cells to Lysis by Human Complement as an Approach for Cancer Gene Therapy, Adv Exp Med Biol, vol.451, pp.359-363, 1998.
DOI : 10.1007/978-1-4615-5357-1_56

C. Link, . Jr, T. Seregina, R. Atchison, A. Hall et al., Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy, Anticancer Res, vol.18, pp.2301-2308, 1998.

R. Unfer, D. Hellrung, C. Link, and . Jr, Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galacto- syl-transferase: a novel suicide gene for cancer gene therapy, Cancer Res, vol.63, pp.987-993, 2003.

M. Aubert, C. Crotte, J. Bernard, D. Lombardo, M. Sadoulet et al., Decrease of human pancreatic cancer cell tumorigenicity by ?1,3galactosyltransferase gene transfer, International Journal of Cancer, vol.116, issue.6, pp.910-918, 2003.
DOI : 10.1002/ijc.11470

G. Dachs, G. Dougherty, I. Stratford, and D. Chaplin, Targeting gene therapy to cancer: a review, Oncol Res, vol.9, pp.313-325, 1997.

C. Ring, P. Blouin, L. Martin, H. Hurst, and N. Lemoine, Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme, Gene Therapy, vol.4, issue.10, pp.1045-1052, 1997.
DOI : 10.1038/sj.gt.3300510

P. Manley, G. Martiny-baron, J. Schlaeppi, and J. Wood, Therapies directed at vascular endothelial growth factor, Expert Opinion on Investigational Drugs, vol.295, issue.1, pp.1715-1736, 2002.
DOI : 10.1021/jm990345w

D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich et al., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, vol.235, issue.4785, pp.177-182, 1987.
DOI : 10.1126/science.3798106

M. Kraus, N. Popescu, S. Amsbaugh, and C. King, Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms, Embo J, vol.6, pp.605-610, 1987.

S. Menard, S. Pupa, M. Campiglio, and E. Tagliabue, Biologic and therapeutic role of HER2 in cancer, Oncogene, vol.22, issue.42, pp.6570-6578, 2003.
DOI : 10.1038/sj.onc.1206779

P. Brennan, T. Kumagai, A. Berezov, R. Murali, M. Greene et al., HER2/Neu: mechanisms of dimerization/oligomerization, Oncogene, vol.19, issue.53, pp.6093-6101, 2000.
DOI : 10.1038/sj.onc.1203967

F. Leone, E. Perissinotto, G. Cavalloni, V. Fonsato, S. Bruno et al., Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells, Journal of Leukocyte Biology, vol.74, issue.4, pp.593-601, 2003.
DOI : 10.1189/jlb.0203068

D. Slamon, W. Godolphin, L. Jones, J. Holt, S. Wong et al., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, vol.244, issue.4905, pp.707-712, 1989.
DOI : 10.1126/science.2470152

B. Li, S. Harlow, R. Budnick, D. Sheedy, and C. Stewart, Detection of HER-2/neu oncogene amplification in flow cytometry-sorted breast ductal cells by competitive polymerase chain reaction, Cancer, vol.84, issue.11, pp.2771-2778, 1994.
DOI : 10.1002/1097-0142(19940601)73:11<2771::AID-CNCR2820731120>3.0.CO;2-K

E. Lyon, A. Millson, M. Lowery, R. Woods, and C. Wittwer, Quantification of HER2/neu gene amplification by competitive pcr using fluorescent melting curve analysis, Clin Chem, vol.47, pp.844-851, 2001.

S. Wang and M. Hung, Transcriptional targeting of the HER-2/ neu oncogene, Drugs Today, vol.36, pp.835-843, 2000.

L. Coussens, T. Yang-feng, Y. Liao, E. Chen, A. Gray et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science, vol.230, issue.4730, pp.1132-1139, 1985.
DOI : 10.1126/science.2999974

L. Klapper, S. Glathe, N. Vaisman, N. Hynes, G. Andrews et al., The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors, Proceedings of the National Academy of Sciences, vol.95, issue.12, pp.4995-5000, 1999.
DOI : 10.1073/pnas.95.12.6809

T. Holbro, G. Civenni, and N. Hynes, The ErbB receptors and their role in cancer progression, Experimental Cell Research, vol.284, issue.1, pp.99-110, 2003.
DOI : 10.1016/S0014-4827(02)00099-X

L. Yu, S. Kamo, and M. Tagawa, Identification of a minimal c-erbB-2 promoter region that mediates preferential expression of a linked foreign gene in human breast cancer cells, International Journal of Oncology, vol.20, pp.607-610, 2002.
DOI : 10.3892/ijo.20.3.607

S. Yu, T. Von-ruden, P. Kantoff, C. Garber, M. Seiberg et al., Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells., Proceedings of the National Academy of Sciences, vol.83, issue.10, pp.3194-3198, 1986.
DOI : 10.1073/pnas.83.10.3194

J. Lefebvre, V. Giordanengo, M. Limouse, A. Doglio, M. Cucchiarini et al., Altered glycosylation of leukosialin, CD43, in HIV-1-infected cells of the CEM line, Journal of Experimental Medicine, vol.180, issue.5, pp.1609-1617, 1994.
DOI : 10.1084/jem.180.5.1609

V. Giordanengo, S. Bannwarth, C. Laffont, V. Van-miegem, A. Harduin-lepers et al., Cloning and Expression of cDNA for a Human Gal(beta1-3)GalNAc alpha2,3-Sialyltransferase from the CEM T-Cell Line, European Journal of Biochemistry, vol.69, issue.2, pp.558-566, 1997.
DOI : 10.1074/jbc.270.36.20987

M. Wright, J. Grim, J. Deshane, M. Kim, T. Strong et al., An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2, Gene Therapy, vol.4, issue.4, pp.317-322, 1997.
DOI : 10.1038/sj.gt.3300372

T. Brodowicz, C. Wiltschke, A. Budinsky, M. Krainer, G. Steger et al., Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro, International Journal of Cancer, vol.7, issue.6, pp.875-879, 1997.
DOI : 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3

R. Kumar, M. Mandal, A. Lipton, H. Harvey, and C. Thompson, Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifeninduced apoptosis in human MCF-7 breast cancer cells, Clin Cancer Res, vol.2, pp.1215-1219, 1996.

H. Kurokawa, A. Lenferink, J. Simpson, P. Pisacane, M. Sliwkowski et al., Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells, Cancer Res, vol.60, pp.5887-5894, 2000.

S. Child, M. Miller, and A. Geballe, Cell type-dependent and -independent control of HER-2/neu translation, The International Journal of Biochemistry & Cell Biology, vol.31, issue.1, pp.201-213, 1999.
DOI : 10.1016/S1357-2725(98)00068-5

F. Graham, J. Smiley, W. Russell, and R. Nairn, Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, Journal of General Virology, vol.36, issue.1, pp.59-74, 1977.
DOI : 10.1099/0022-1317-36-1-59

M. Quinlan, Expression of antisense E1A in 293 cells results in altered cell morphologies and cessation of proliferation, Oncogene, vol.8, pp.257-265, 1993.

D. Kamei, M. Murakami, Y. Nakatani, Y. Ishikawa, T. Ishii et al., Potential Role of Microsomal Prostaglandin E Synthase-1 in Tumorigenesis, Journal of Biological Chemistry, vol.278, issue.21, pp.19396-19405, 2003.
DOI : 10.1074/jbc.M213290200

C. Springer and I. Niculescu-duvaz, Prodrug-activating systems in suicide gene therapy, Journal of Clinical Investigation, vol.105, issue.9, pp.1161-1167, 2000.
DOI : 10.1172/JCI10001

U. Galili, E. Rachmilewitz, A. Peleg, and I. Flechner, A unique natural human IgG antibody with anti-alpha-galactosyl specificity, Journal of Experimental Medicine, vol.160, issue.5, pp.1519-1531, 1984.
DOI : 10.1084/jem.160.5.1519

A. Good, D. Cooper, A. Malcolm, R. Ippolito, E. Koren et al., Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans, Transplant Proc, vol.24, pp.559-562, 1992.

A. Thall, H. Murphy, and J. Lowe, 3-Galactosyltrans- ferase-deficient mice produce naturally occurring cytotoxic anti-Gal antibodies, Transplant Proc, vol.1, issue.28, pp.556-557, 1996.

E. Salvaris, H. Gock, W. Han, L. Murray-segal, H. Barlow et al., Naturally acquired anti-alphaGal antibodies in a murine allograft model similar to delayed xenograft rejection, Xenotransplantation, vol.62, issue.1, pp.42-47, 2000.
DOI : 10.1016/S1050-1738(98)00021-8

T. Sawada, O. Yamada, N. Yoshimura, K. Hatori, S. Fuchinoue et al., Xenoantigen, an alphaGal epitope-expression construct driven by the hTERT-promoter, specifically kills human pancreatic cancer cell line, Cancer Cell International, vol.2, issue.1, pp.14-20, 2002.
DOI : 10.1186/1475-2867-2-14

C. Arteaga, W. Chinratanalab, and M. Carter, Inhibitors of HER2/neu (erbB-2) signal transduction, Seminars in Oncology, vol.28, pp.30-35, 2001.
DOI : 10.1016/S0093-7754(01)90106-X

H. Hurst, Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment, Breast Cancer Research, vol.19, issue.6, pp.395-398, 2001.
DOI : 10.1093/emboj/19.9.2024

G. Scott, C. Chang, K. Erny, F. Xu, W. Fredericks et al., Ets regulation of the erbB2 promoter, Oncogene, vol.19, issue.55, pp.6490-6502, 2000.
DOI : 10.1038/sj.onc.1204041

X. Xing, S. Wang, W. Xia, Y. Zou, R. Shao et al., The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis, Nat Med, vol.6, pp.189-195, 2000.

D. Yu, T. Suen, D. Yan, L. Chang, and M. Hung, Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products., Proceedings of the National Academy of Sciences, vol.87, issue.12, pp.4499-4503, 1990.
DOI : 10.1073/pnas.87.12.4499

J. Chang, W. Xia, R. Shao, F. Sorgi, G. Hortobagyi et al., The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer, Oncogene, vol.14, issue.5, pp.561-568, 1997.
DOI : 10.1038/sj.onc.1200861

D. Yu and M. Hung, Overexpression of ErbB2 in cancer and ErbB2-targeting strategies, Oncogene, vol.19, issue.53, pp.6115-6121, 2000.
DOI : 10.1038/sj.onc.1203972

P. Beckhove, F. Schutz, I. Diel, E. Solomayer, G. Bastert et al., Efficient engraftment of human primary breast cancer transplants in nonconditioned NOD/Scid mice, International Journal of Cancer, vol.90, issue.4, pp.444-453, 2003.
DOI : 10.1002/ijc.11125

A. Thall, P. Maly, and J. Lowe, Oocyte Gal??1,3Gal Epitopes Implicated in Sperm Adhesion to the Zona Pellucida Glycoprotein ZP3 Are Not Required for Fertilization in the Mouse, Journal of Biological Chemistry, vol.270, issue.37, pp.21437-21440, 1995.
DOI : 10.1074/jbc.270.37.21437

R. Tearle, M. Tange, Z. Zannettino, M. Katerelos, T. Shinkel et al., THE ??-1,3-GALACTOSYLTRANSFERASE KNOCKOUT MOUSE, Transplantation, vol.61, issue.1, pp.13-19, 1996.
DOI : 10.1097/00007890-199601150-00004